Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 6, 2014, Pages 3224-3234

  Kim, Sang Kyum ^a   Jung, Woo Hee ^a   Koo, Ja Seung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast cancer; Molecular subtype; YAP

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PHOSPHOPROTEIN; PROGESTERONE RECEPTOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; PHENOTYPE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84904356717     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006; 103: 12405-12410.
2. Zhao B, Li L, Lei Q and Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010; 24: 862-874.
3. Basu S, Totty NF, Irwin MS, Sudol M and Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11: 11-23.
4. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA and Anders RA. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008; 39: 1582-1589.
5. Tufail R, Jorda M, Zhao W, Reis I and Nawaz Z. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat 2012; 131: 743-750.
6. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, Pardo O, Crook T, Mein CA, Lemoine NR, Jones LJ and Basu S. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008; 15: 1752-1759.
7. Zhi X, Zhao D, Zhou Z, Liu R and Chen C. YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor. Am J Pathol 2012; 180: 2452-2461.
8. Wang X, Su L and Ou Q. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer 2012; 48: 1227-1234.
9. Elston CW and Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
10. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL and Wolff AC. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
11. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM and Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
12. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B and Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
13. Sheen-Chen SM, Huang CY, Tsai CH, Liu YW, Wu SC, Huang CC, Eng HL, Chan YC, Ko SF and Tang RP. Yes-associated protein is not an independent prognostic marker in breast cancer. Anticancer Res 2012; 32: 3321-3325.
14. Vlug EJ, van de Ven RA, Vermeulen JF, Bult P, van Diest PJ and Derksen PW. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr) 2013; 36: 375-384.
15. Di Fiore PP, Segatto O, Lonardo F, Fazioli F, Pierce JH and Aaronson SA. The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol Cell Biol 1990; 10: 2749-2756.
16. Quan T, Xu Y, Qin Z, Robichaud P, Betcher S, Calderone K, He T, Johnson TM, Voorhees JJ and Fisher GJ. Elevated YAP and Its Downstream Targets CCN1 and CCN2 in Basal Cell Carcinoma: Impact on Keratinocyte Proliferation and Stromal Cell Activation. Am J Pathol 2014; 184: 937-43.
17. Reddy P, Deguchi M, Cheng Y and Hsueh AJ. Actin cytoskeleton regulates Hippo signaling. PLoS One 2013; 8: e73763.
18. Desmouliere A, Guyot C and Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004; 48: 509-517.
19. Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DS, Mills GB, Sood A and Lee JS. Activation of YAP1 Is Associated with Poor Prognosis and Response to Taxanes in Ovarian Cancer. Anticancer Res 2014; 34: 811-817.
20. Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, Zeng YX, Zhou FJ and Xie D. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer 2013; 13: 349.
21. Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W and Zhu Q. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One 2013; 8: e65539.
22. Yeo MK, Kim SH, Kim JM, Huang SM, Kim MR, Song KS and Kim KH. Correlation of expression of phosphorylated and non-phosphorylated Yes-associated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population. Anticancer Res 2012; 32: 3835-3840.
23. Song M, Cheong JH, Kim H and Noh SH. Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res 2012; 32: 3827-3834.
24. Wang Y, Dong Q, Zhang Q, Li Z, Wang E and Qiu X. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 2010; 101: 1279-1285.
25. Lehn S, Tobin NP, Sims AH, Stal O, Jirstrom K, Axelson H and Landberg G. Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response. BMC Cancer 2014; 14: 119.